Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma
This study has been completed.
Information provided by:
First received: August 2, 2005
Last updated: May 15, 2007
Last verified: May 2007
The study is designed to study the effectiveness of 123I-mIBG as a diagnostic imaging agent in evaluating patients with known or suspected neuroblastoma or phaeochromocytoma.
Drug: 123I-mIBG (meta-iodobenzylguanidine)
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Resource links provided by NLM:
Genetics Home Reference related topics: hereditary paraganglioma-pheochromocytoma neuroblastoma nonsyndromic paraganglioma
Genetic and Rare Diseases Information Center resources: Neuroblastoma Pheochromocytoma Neuroepithelioma Paragangliomas 1U.S. FDA Resources
Further study details as provided by GE Healthcare:
Primary Outcome Measures:
- - To demonstrate that 123I-mIBG planar scintigraphy is sensitive and specific in confirming or excluding the diagnoses of neuroblastoma and phaeochromocytoma.
Secondary Outcome Measures:
- To determine the incremental value of single-photon emission computed tomography (SPECT) for improving the sensitivity and specificity of 123I-mIBG planar scintigraphy for the diagnoses of neuroblastoma and phaeochromocytoma.
- To collect safety data on 123I-mIBG.
|Study Start Date:||July 2005|
Contacts and Locations